Current Investors
Why Raydiant Oximetry?
Novel technology
Raydiant Oximetry is poised to deliver a first-to-market commercial product that meets the goals of all its key stakeholders - patients, providers and healthcare systems.
World-Class Team
Raydiant has a technical team with more than 150 years of combined experience in pulse oximetry working in collaboration with seasoned commercial business leaders to bring these innovative technologies to market.
Breakthrough status
Our technology has already received the coveted FDA Breakthrough designation and is protected by four families of patents.
Global Impact
The company is pursuing a dual market strategy to develop solutions for low and middle-income countries enabled by grants from the Bill & Melinda Gates foundation and the NIH.
Seamless integration
The technology seamlessly integrates with current FHR monitoring, causing no disruption to existing hospital workflows.
Strong support
Raydiant Oximetry has been funded by the NIH, NSF, and private accredited investors.
Related News
Invest in Lumerah
Want to learn more about the investment opportunity? Send us a message and we’ll be in touch as soon as possible.